The effect of resveratrol supplementation on serum levels of asymmetric de‐methyl‐arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double‐blind controlled trial
Mahtab Tabatabaie, Shima Abdollahi, Amin Salehi‐Abargouei, Cain C. T. Clark, Elham Karimi‐Nazari, Hossein Fallahzadeh, Masoud Rahmanian, Hassan Mozaffari–Khosravi
Abstract
The present study sought to investigate the effect of micronized resveratrol supplementation on serum levels of asymmetric de-methyl-arginine (ADMA) and paraoxonase-1 (PON1) activity in patients with type 2 diabetes (T2D). In this double-blinded randomized trial, 76 patients with T2D were recruited. Participants were randomly assigned to consume 1,000 mg resveratrol or placebo capsules (methylcellulose) per day, for 8 weeks. Serum levels of ADMA and PON1 enzyme activity were measured at the beginning and end of the intervention using the enzyme-linked immunosorbent assay method. In total, 71 participants completed the study. Our results showed that resveratrol significantly decreased serum levels of ADMA (-0.16 ± 0.11, p < .001) and improved PON1 enzyme activity (15.39 ± 13.99, p < .001) compared with placebo, after adjusting for confounding factors (age, sex, and baseline body mass index). Our findings suggest that 8-week resveratrol supplementation may produce beneficial effects on serum levels of ADMA and PON1 enzyme activity in patients with T2DM. However, further research is needed to confirm the veracity of these results.